Antigen Delivery to Lymphatic System for Rapid Desensitization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inducing tolerance to allergens, such as allergy shots, are invasive, time-consuming, and not always effective in providing rapid relief, leaving a significant unmet medical need for better and less invasive desensitization techniques.
Innovation Solution
Development of compositions and methods that deliver antigens directly to the lymphatic system using microneedles, microparticles, or autologous transfusion, aiming to increase immunoglobulin G levels while minimizing immunoglobulin E levels, and shifting the immune response from Th2 to Th1 to achieve rapid desensitization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional allergy shots are used to induce tolerance to allergens, then long-term relief is achieved, but the treatment is invasive and time-consuming with delayed symptom improvement
Solution Approach 1:
The patent extracts the antigen delivery directly to the lymphatic system, bypassing traditional subcutaneous injection sites. This is achieved by injecting compositions into specific lymphatic vessels or nodes, thereby extracting the inefficiency of traditional delivery routes and achieving faster immune modulation.
Solution Approach 2:
The patent uses the lymphatic system as an intermediary pathway to deliver antigens directly to immune cells. By utilizing this natural biological transport system, the treatment achieves rapid desensitization without the prolonged timeline of traditional allergy shots.
2Reliability
If traditional allergy shots are used to induce tolerance to allergens, then immunity is developed over time, but the treatment is invasive requiring repeated injections
Solution Approach 1:
The patent extracts the antigen delivery directly to the lymphatic system, bypassing traditional subcutaneous injection sites. This is achieved by injecting compositions into specific lymphatic vessels or nodes, thereby extracting the inefficiency of traditional delivery routes and achieving faster immune modulation.
Solution Approach 2:
The patent changes the delivery parameter from subcutaneous injection to direct lymphatic injection. This parameter change in administration route reduces invasiveness while improving the speed and efficiency of tolerance induction.
3Reliability
If traditional allergy shots are used to induce tolerance to allergens, then symptom relief is achieved, but rapid desensitization is not accomplished
Solution Approach 1:
The patent uses the lymphatic system as an intermediary pathway to deliver antigens directly to immune cells. By utilizing this natural biological transport system, the treatment achieves rapid desensitization without the prolonged timeline of traditional allergy shots.
Solution Approach 2:
The patent changes the delivery parameter from subcutaneous injection to direct lymphatic injection. This parameter change in administration route reduces invasiveness while improving the speed and efficiency of tolerance induction.
Data Source
Figure 1
AI summary
Methods and compositions for delivering antigens to the lymphatic system in doses that desensitize patients to future exposure to antigens have been developed. Rapid desensitization is achieved by introducing small quantities of antigen into the lymphatic system. In preferred embodiments, the compositions are administered to yield therapeutically effective levels of antigen within the lymph, where macrophages reside in the greatest concentration, by intradermal administration, using for example, microneedles or microparticles, oral administration, using for example, enteric coated capsules or tablets, or autologous transfusion. In some embodiments, the methods and compositions for delivering antigens orally achieve uptake by the Peyer's patches of the small intestines.